Effect of reactive-aldehydes on the modification and dysfunction of human serum albumin

Journal of Pharmaceutical Sciences

Volumn 99, Issue 3, 2010, Pages 1614-1625

  Mera, Katsumi ^a   Takeo, Kazuhiro ^a   Izumi, Miyoko ^a   Maruyama, Toru ^a   Nagai, Ryoji ^b   Otagiri, Masaki ^a,c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JAPAN WOMEN'S UNIVERSITY   (Japan)

^c SOJO UNIVERSITY   (Japan)

Author keywords

Albumin; Distribution; Drug interactions; Protein aggregation; Protein binding

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALDEHYDE DERIVATIVE; ARGININE; GLUCOSE; GLUCOSONE; GLYCERALDEHYDE; GLYCOLALDEHYDE DEHYDROGENASE; GLYOXAL; HUMAN SERUM ALBUMIN; IMIDAZOLINE DERIVATIVE; KETOPROFEN; LYSINE; METHYLGLYOXAL; PYRIDINE; SCHIFF BASE; UNCLASSIFIED DRUG; WARFARIN;

AGAR GEL ELECTROPHORESIS; AMINO ACID ANALYSIS; ARTICLE; CORRELATION ANALYSIS; DEGRADATION; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOLYSIS; HUMAN; IMMUNOREACTIVITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; PROTEIN MODIFICATION;

EID: 76649085190     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21927     Document Type: Article

References (42)

1. Nakajou K, Watanabe H, Kragh-Hansen U, Maruyama T, Otagiri M. 2003. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta 1623:88-97.
2. Bourdon E, Loreau N, Blache D. 1999. Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J 13:233-244.
3. Kumar PA, Kumar MS, Reddy GB. 2007. Effect of glycation on alpha-crystallin structure and chaper-one-like function. Biochem J 408:251-258.
4. Ookawara T, Kawamura N, Kitagawa Y, Taniguchi N. 1992. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by glycation reaction. Implication of reactive oxygen species. J Biol Chem 267:18505-18510.
5. Thornalley PJ, Langborg A, Minhas HS. 1999. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116.
6. Nagai R, Unno Y, Hayashi MC, Masuda S, Hayase F, Kinae N, Horiuchi S. 2002. Peroxynitrite induces formation of N(epsilon)-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: Novel pathways for protein modification by peroxynitrite. Diabetes 51:2833-2839.
7. Nagai R, Hayashi CM, Xia L, Takeya M, Horiuchi S. 2002. Identification in human atherosclerotic lesions of GA-pyridine, a novel structure derived from glycolaldehyde-modified proteins. J Biol Chem 277:48905-48912.
8. McLellan AC, Thornalley PJ, Benn J, Sonksen PH. 1994. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 87:21-29.
9. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. 2003. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110-2120.
10. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. 2003. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9:294-299.
11. Anderson MM, Hazen SL, Hsu FF, Heinecke JW. 1997. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 99:424-432.
12. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. 1999. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl) lysine on proteins: A mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104:103-113.
13. Koito W, Araki T, Horiuchi S, Nagai R. 2004. Conventional antibody against Nepsilon-(carboxymethyl) lysine (CML) shows cross-reaction to Nepsilon-(carboxyethyl)lysine (CEL): Immunochemical quantification of CML with a specific antibody. J Biochem (Tokyo) 136:831-837.
14. Nagai R, Matsumoto K, Ling X, Suzuki H, Araki T, Horiuchi S. 2000. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 49:1714-1723.
15. Mera K, Nagai M, Brock JW, Fujiwara Y, Murata T, Maruyama T, Baynes JW, Otagiri M, Nagai R. 2008. Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products. J Immunol Methods 334:82-90.
16. Nagai R, Fujiwara Y, Mera K, Motomura K, Iwao Y, Tsurushima K, Nagai M, Takeo K, Yoshitomi M, Otagiri M, Ikeda T. 2008. Usefulness of antibodies for evaluating the biological significance of AGEs. Ann NY Acad Sci 1126:38-41.
17. Nagai R, Fujiwara Y, Mera K, Yamagata K, Sakashita N, Takeya M. 2008. Immunochemical detection of Nepsilon-(carboxyethyl)lysine using a specific antibody. J Immunol Methods 332:112-120.
18. Himmelfarb J, McMonagle E. 2001. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 60:358-363.
19. Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Tomita K, Otagiri M. 2005. Oxidation and carboxy methyl lysine-modification of albumin: Possible involvement in the progression of oxidative stress in hemodialysis patients. Hypertens Res 28: 973-980.
20. Chen RF. 1967. Removal of fatty acids from serum albumin by charcoal treatment. J Biol Chem 242: 173-181.
21. Whistler RL, Wolfrom ML. 1963. Methods in carbohydrate chemistry. London: Academic Press. pp. 421-423.
22. Madson M, Feather MS. 1981. An improved preparation of 3-deoxy-D-erythro-hexo-2-ulose via the bis(benzoylhydrazone) and some related constitutional studies. Carbohydr Res 94:183-191.
23. Nagai R, Mera K, Nakajou K, Fujiwara Y, Iwao Y, Imai H, Murata T, Otagiri M. 2007. The ligand activity of AGE-proteins to scavenger receptors is dependent on their rate of modification by AGEs. Biochim Biophys Acta 1772:1192-1198.
24. Fields R. 1971. The measurement of amino groups in proteins and peptides. Biochem J 124:581-590.
25. Westwood ME, Thornalley PJ. 1995. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J Protein Chem 14: 359-372.
26. Smith RE, MacQuarrie R. 1978. A sensitive fluorometric method for the determination of arginine using 9,10-phenanthrenequinone. Anal Biochem 90:246-255.
27. Horiuchi S, Araki N, Morino Y. 1991. Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J Biol Chem 266:7329-7332.
28. Glenn JV, Mahaffy H, Wu K, Smith G, Nagai R, Simpson DA, Boulton ME, Stitt AW. 2009. Advanced glycation end product (AGE) accumulation on Bruch's membrane: Links to age-related RPE dysfunction. Invest Ophthalmol Vis Sci 50: 441-451.
29. Jono T, Nagai R, Lin X, Ahmed N, Thornalley PJ, Takeya M, Horiuchi S. 2004. Nepsilon-(carboxymethyl) lysine and 3-DG-imidazolone are major AGE structures in protein modification by 3-deoxyglucosone. J Biochem (Tokyo) 136:351-358.
30. Jono T, Kimura T, Takamatsu J, Nagai R, Miyazaki K, Yuzuriha T, Kitamura T, Horiuchi S. 2002. Accumulation of imidazolone, pentosidine and N(epsilon)-(carboxymethyl)lysine in hippocampal CA4 pyramidal neurons of aged human brain. Pathol Int 52:563-571.
31. Watanabe H, Kragh-Hansen U, Tanase S, Nakajou K, Mitarai M, Iwao Y, Maruyama T, Otagiri M. 2001. Conformational stability and warfarinbinding properties of human serum albumin studied by recombinant mutants. Biochem J 357:269-274.
32. Watanabe H, Tanase S, Nakajou K, Maruyama T, Kragh-Hansen U, Otagiri M. 2000. Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem J 349: 813-819.
33. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. 1996. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50:627-634.
34. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME. 2001. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44:108-114.
35. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. 1991. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88:11555-11558.
36. Ahmed N, Dobler D, Dean M, Thornalley PJ. 2005. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280:5724-5732.
37. Namiki M, Hayashi T. 1975. Development of novel free radicals during the amino-carbonyl reaction of sugars with amino acids. J Agric Food Chem 23: 487-491.
38. Glomb MA, Monnier VM. 1995. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 270:10017-10026.
39. Acharya AS, Manning JM. 1983. Reaction of glycolaldehyde with proteins: Latent crosslinking potential of alpha-hydroxyaldehydes. Proc Natl Acad Sci USA 80:3590-3594.
40. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ. 2005. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48:1590-1603.
41. Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O, Dawnay A. 2000. Mass spectrometric monitoring of albumin in uremia. Kidney Int 58: 2228-2234.
42. Otagiri M. 2005. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 20:309-323.